OBJECTIVE: To observe the effect of the polyglycol (PEG) modification of trimeric ? peptide(?3) on it’s anti-metastasis ability. METHODS: Using adhesion test to study the effects of ?3 and ?3-PEG on the adhesion of tumor cells to FN. Using artificial basal membrane to study the effects of ?3 and ?3-PEG on the invasion and recombination of basal membrane of tumor cells. RESULTS: Comparing to negative control,?3 and ?3-PEG could both inhibit the adhesion of SMMC-7721 and HCCLM6 tumor cells to FN with time-dependently(P

Tremendous success has emerged in chimeric antigen receptor (CAR)-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.

Objective:To investigate and analyze the rational use of anti-tumor immune enhancement drugs in our hospital. Meth-ods:The annual use data of anti-tumor immune enhancement drugs in our hospital in 2015 were collected, and then statistically ana-lyzed and evaluated combing with the medical history information. Results: There were 12 varieties and 19 specifications of adjuvant anti-tumor immune enhancement drugs in our hospital, which accounted for 15. 87% of the total sum. Totally 25 481 patients used ad-juvant anti-tumor immune enhancement drugs, which occupied 29. 84% of the total medicine afford. The adjuvant anti-tumor immune enhancement drugs showed lots of irrational use in clinics, and the main irrationity was overuse and off-label use. Conclusion: It is necessary to strengthen prescription evaluation for anti-tumor immune enhancement drugs, which needs controlled and rational use.

BACKGROUND:It is reported that vitamin C can induce bone marrow mesenchymal stem cel s differentiating into osteoblasts, and promote bone repair and regeneration. However, vitamin C solution is unstable, so a carrier is necessary. OBJECTIVE:To observe the loading and control ed-release abilities of calcium phosphate used as the carrier ofvitamin C. METHODS:Calcium phosphate particles loaded with vitamin C were fabricated using chemical precipitation method, and the final concentration of vitamin C was 0, 0.1, 2 and 4 mmol/L, respectively. The drug-loaded capacity was detected. The release of vitamin from calcium phosphate nanoparticles in the simulate body fluid and ultrasonic environment was respectively evaluated. MC3T3-E1 cel s were co-cultured with calcium phosphate nanoparticles loaded with 2 mmol/L vitamin C, or calcium phosphate nanoparticles only. The cel proliferation was detected at 1, 3, 5 and 7 days of culture, and the alkaline phasphatase activity was detected at 1, 5, 10 and 15 days of culture. RESULTS AND CONCLUSION:The drug-loaded contents of calcium phosphate nanoparticles loading 0, 0.1, 2 and 4 mmol/L vitamin C were (59.9±5.4)%, (87.2±1.2)%and (28.4±26.3)%, respectively. Under normal environment, al samples could release vitamin C persistently, but the initial release speed of the particles carrying 0.1 and 2 mmol/L vitamin C was lower than that of particles carrying 4 mmd/L vitamin. Under ultrasonic environment, 2 mmol/L vitamin C-loaded calcium phosphate particles exhibited a quick release speed firstly that reached 5-15%, fol owed by a slow release speed. When ultrasonic powers kept at 75, 105 and 150 W, the release duration of vitamin C was 220, 340 and 260 minutes, respectively. MC3T3-E1 cel proliferation did not change after co-cultured with 2 mmol/L vitamin C-loaded calcium phosphate particles but the alkaline phosphatase activity was improved. These results suggest that calcium phosphate particles can be used as the carrier of vitamin C.

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin's lymphomas (NHLs). MCL comprises distinct subtypes with different pathological characteristics and clinical features. However, MCL remains incurable by intensified first-line regimens con-taining cytarabine and involving consolidation with high-dose therapy and autologous stem cell transplantation. Recently discovered somatic mutations and aberrant intracellular signaling pathways have been demonstrated to play an essential role in the pathogenesis of MCL. The related novel therapeutics, such as Btk inhibitors, PI3K inhibitors, and immune modulators, have exhibited promising ther-apeutic effects on untreated or even relapsed/refractory MCL. The development of an efficient combination therapy is urgently need-ed to improve the survival of MCL patients in the future.

Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma (B-NHL),but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug.Recently,many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma.The advances in translational research field were summarized in this manuscript.

Advances in clinical transformation research has facilitated discovery of a number of novel somatic mutations and aberrant intracellular signaling pathways involved in malignant proliferative B-cell lymphoma.Meanwhile,small molecular inhibitors targeting those mutation genes or signaling pathways have also been shown to be effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma.This paper reviewed important discoveries in clinical transformation research in lymphoma field in 2013.

Objective The purpose of this study was to evaluate the importance of the interhospital transport of critically ill pediatric patients by analyzing the epidemic characteristics of pediatric patients transported from 2009 to 2012.Methods Nine thousand two hundred and thirty-one referral patients from January 2009 to June 2012 were evaluated by a cross-section study.Epidemiological data such as sex,age,seasons,and referral radius were collected.Results Among all the interhospital transport of critically ill pediatric patients,male to female ratio was nearly 2.24 to 1 and 87.39％ (8067/9231) patients were neonates and infants.Of all patients,66.32％ (6122/9231) patients were from department of pediatrics,neonatology or gynaecology and obstetrics in referring hospitals.The distribution of referring department among years was statistically significant in referring patients (x2 =227.53,P ＜ 0.000 1).Among the patients,56.88％ (5251/9231) were transported over 150km radius and only 12.18％ (1124/9231) patients in 50 km.52.89％(4882/9231) were transported in spring and winter.The seasonal distribution of interhospital transport of critically ill pediatric patients was statistically significant(x2 =1201.88,P ＜0.000 1).The majority of referral telephones were received between 9 AM to 12 AM.Conclusion With the limitation of equipment and technical measure in primary hospitals,critically ill pediatric patients should be transported to tertiary hospitals.According to the epidemiological characteristics of interhospital transport of critically ill pediatric patients,some measures should be adopted for the timely,safe and effective interhospital transportation.

Side population cells (SPs) are selected by the efflux features of fluorescent dye Hoechst33342.SPs have the characteristics of cancer stem cells,and play an extremely important role in the occurrence and development of tumors.At present,the SPs in common types of malignant tumor have been studied extensively at home and abroad.The study of SPs may shed some light on the diagnosis and treatment of cancer.

About the malignant tumor in China,the hepatocellular carcinoma mortality is second only to lung cancer and serious threat to the life and health of the masses.Furthermore,because most patients has been in advanced cancer during medical treatment,so had lost the chance of one-stage surgical resection.However,the sensitivity of hepatocellular carcinoma to chemotherapy,radiotherapy and other treatments are poor.Transcatheter arterial chemoembolization is the main method of the treatment for patients those have lost the chance of operation,though the clinical effect is significant,the inadequate is also presence,such as tumor necrosis,incompletely clear,residual tumor nidus and the damage of the immune function after operation.Recombinant adenovirus p53 gene can validly infect tumor cells,transcription and expression of p53 protein,it also regulate the expression of related genes inhibiting tumor cell growth and induce cell apoptosis directly or indirectly.It is increasingly highly attention that recombincanting rAd-p53 with transcatheter arterial chemoembolization(TACE) to treat hepatocellular carcinoma.In order to evaluate the clinical value and promising future,we will make a brief summary for the research progress in this area in recent years.